Alaunos Therapeutics Inc (TCRT) Stock Price, Quote & News

Company Profile

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression. In addition, the company develops hunTR TCR discovery platform to target driver mutations. Alaunos T...

Industry: Biotechnology

Sector: Healthcare

Phone: 346 355 4099

Website: www.alaunos.com

Address:

2617 Bissonnet Street, Suite 233, Houston, United States

Moneymastermind99 Aug. 1 at 4:29 PM

🚀 Squeeze Radar: Biotech Meets Meme Mania 🔥 $KZIA holding around $7.80 after ripping to $11+. Low float + Paxalisib pipeline = still a serious breakout candidate. PTs range $13–$15+ 🎯 💊 Biotech Movers: • $MBOT – robotics popper, float <2M • $BIVI – Alzheimer’s name, strong wicks • $TCRT – CAR-T bounce setup near $2.50 📈 Meme Momentum: • $OPEN – +200% run helped avoid Nasdaq delisting • $DNUT – Krispy Kreme hype, 35% short float • $KSS – Kohl’s surged on GME-style short pressure ⚠️ These aren’t safe plays — but they’re moving. Tight risk. Ride momentum, don’t chase late. #KZIA #MBOT #OPEN #DNUT #TCRT #BiotechStocks #MemeStocks #LowFloat #ShortSqueeze #DayTrading

0 · Reply

Moneymastermind99 Aug. 1 at 3:33 PM

🚨 Biotech x Meme Squeeze Watch 🔥 $KZIA still hot at $7.83, cooling off after $11+ spike. Low float, pipeline catalysts (Paxalisib), and analyst PTs up to $15.75 = still in play. 💥 Similar biotech setups: • $MBOT – micro float, robotics runner • $BIVI – Alzheimer’s play, breakout forming • $TCRT – CAR-T name, eyes on $3 • $BCLI – FDA rumors, high short interest 🎯 Meme madness crossover: • $OPEN – +120% squeeze, massive retail flow • $DNUT – Krispy Kreme breakout, riding hype • $KSS – Kohl’s doubled, 49% short float ⚠️ High risk, high reward. Not financial advice — just the momentum I’m tracking. Squeeze season might not be over. #KZIA #Biotech #LowFloat #ShortSqueeze #MemeStocks #OPEN #DNUT #KSS #DayTrading

0 · Reply

Moneymastermind99 Aug. 1 at 2:30 PM

🚨 $KZIA + Biotech Low Floats on Watch 🔬🔥 $KZIA trading at $7.83, down today but still hot after hitting $11+. Low float + volume = squeeze fuel. Watching for bounce to $9.50+, then $13–$15 targets. 💥 Similar setups: • $MBOT – Robotics runner, ultra low float • $BIVI – Alzheimer’s play w/ breakout chart • $TCRT – CAR-T setup, eyeing $3+ • $BCLI – FDA rumors, low float mover All low float. All high risk/reward. All on squeeze watch. Not financial advice — just sharing setups. #KZIA #LowFloat #BiotechStocks #ShortSqueeze #DayTrading

0 · Reply

mosu_trader Jul. 29 at 11:24 AM

$TCRT nice dip to buy, key levels 4.3, 6.2, 7.5

0 · Reply

katanare Jul. 24 at 5:53 PM

$IOVA Drying up the float — classic biotech strategy. Before key catalysts, they wipe out weak hands so no sellers block the move. Controlled selling + absorption = full control before news. This already happened with: • $IMMU (Gilead acquisition) • $SRPT (FDA agreement) • $KPTI, $TCRT, $CLVS (pre-PR or squeeze) Catalyst + float control = explosive setup.

3 · Reply

MadMaverick Jul. 22 at 3:12 PM

$RNXT - Late July Phase III data targeting pancreatic cancer, echoing recent biotech surges: 🔹 $INAB +150% on gene therapy news 🔹 $TCRT +80% after CAR-T trial update 🔹 $RDHL +58% after FDA feedback for trial 🔹 $PMN +145% after Fast Track Designation news Looking for a technical breakout from descending channel attracting swing traders https://chartingdaily.com/RNXT-stock Communicated Disclaimer - Do your own research too.

2 · Reply

KhalidsCapital Jul. 19 at 3:53 AM

GLMD is coiled, forgotten and extremely undervalued. Book value is 10x the share price. No dilution. Catalyst window ends in days. Float is thin, pressure is building, and sentiment can flip in a heartbeat. Perfect setup for a sudden reprice and history shows it can run. $TCRT $CNTB $GLSI $TCRX

0 · Reply

Pipelinepivots Jul. 18 at 5:10 PM

RSLS has real biotech squeeze potential. With a confirmed merger ahead and an ultra-thin float, this setup mirrors past 3–5x runners. No toxic dilution. No hype yet. Just pure structure and timing. It only takes one headline in this sector to set off a chain reaction. $ATNF $CLRB $SHPH $TCRT

0 · Reply

MadMaverick Jul. 16 at 5:19 PM

$RNXT - A compelling biotech play Biotech trades thrive on pivotal trial results. Take recent movers like $INAB or $TCRT, both surged following positive data from Phase II/III trials. For example: $INAB spiked over 150% on favorable gene therapy news $TCRT jumped 80%+ post interim CAR-T trial updates Now we look at RNXT, heading into late July with a Phase III trial data being released, targeting locally advanced pancreatic cancer: - Estimated 400M+ U.S. market - Orphan Drug exclusivity for runway protection - Intra-arterial delivery method that's pioneering the standard of care TA: Flagging on the chart, watching for a breakout that could push toward analyst targets in the $7–11 range. Communicated Disclaimer https://chartingdaily.com/RNXT-stock

2 · Reply

DMAT1681 Jul. 15 at 10:25 AM

$TCRT The stock drops 20% and not a peep of insight?🤔🫡

0 · Reply

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering

May 14, 2025, 8:00 AM EDT - 3 months ago

PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)

ELAB

Nov 14, 2023, 7:30 AM EST - 1 year ago

Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives

Aug 21, 2023, 7:32 AM EDT - 2 years ago

Top 5 Health Care Stocks That Could Blast Off This Month - Allakos (NASDAQ:ALLK), BioLife Solns (NASDAQ:BLFS)

ALLK BLFS KZR

Aug 14, 2023, 4:05 PM EDT - 2 years ago

Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives

Jun 29, 2023, 7:00 AM EDT - 2 years ago

Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies

May 25, 2023, 5:00 PM EDT - 2 years ago

Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting

May 10, 2023, 3:40 PM EDT - 2 years ago

Alaunos Therapeutics, Inc. (TCRT) Q1 2023 Earnings Call Transcript

May 10, 2023, 7:00 AM EDT - 2 years ago

Alaunos Therapeutics Reports First Quarter 2023 Financial Results

May 3, 2023, 8:30 AM EDT - 2 years ago

Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023

Apr 26, 2023, 12:30 PM EDT - 2 years ago

Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Mar 30, 2023, 7:00 AM EDT - 2 years ago

Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors

Mar 29, 2023, 5:30 PM EDT - 2 years ago

Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April

Mar 7, 2023, 10:35 AM EST - 2 years ago

Alaunos Therapeutics, Inc. (TCRT) Q4 2022 Earnings Call Transcript

Mar 7, 2023, 7:00 AM EST - 2 years ago

Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Feb 28, 2023, 4:01 PM EST - 2 years ago

Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023

Jan 9, 2023, 8:30 AM EST - 2 years ago

Alaunos Therapeutics Highlights Strategic Priorities and Anticipated Portfolio Milestones for 2023

Nov 29, 2022, 9:01 AM EST - 2 years ago

Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock

Nov 28, 2022, 4:01 PM EST - 2 years ago

Alaunos Therapeutics Announces Proposed Public Offering of Common Stock

Nov 21, 2022, 2:13 PM EST - 2 years ago

Alaunos Therapeutics Still Waiting For Home Run

Nov 14, 2022, 2:10 PM EST - 2 years ago

Alaunos Therapeutics, Inc. (TCRT) Q3 2022 Earnings Call Transcript

Nov 14, 2022, 7:00 AM EST - 2 years ago

Alaunos Therapeutics Reports Third Quarter 2022 Financial Results

Nov 8, 2022, 8:30 AM EST - 2 years ago

Alaunos Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022

Nov 7, 2022, 8:00 AM EST - 2 years ago

Alaunos Therapeutics to Present Data Highlighting its hunTR™ TCR Discovery Platform at the Society for Immunotherapy of Cancer 2022 Annual Meeting

Sep 21, 2022, 8:30 AM EDT - 3 years ago

Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference

Sep 14, 2022, 9:28 PM EDT - 3 years ago

Alaunos Therapeutics - T-Cell Therapies

Sep 7, 2022, 8:30 AM EDT - 3 years ago

Alaunos Therapeutics to Participate in Upcoming Investor Conferences in September

Aug 31, 2022, 4:00 PM EDT - 3 years ago

Alaunos: Taking Autologous T-Cell Receptor Therapies To The Next Step

Aug 24, 2022, 3:00 PM EDT - 3 years ago

Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference

Aug 15, 2022, 12:01 PM EDT - 3 years ago

Alaunos Therapeutics, Inc. (TCRT) CEO Kevin Boyle on Q2 2022 Results - Earnings Call Transcript

Aug 15, 2022, 7:00 AM EDT - 3 years ago

Alaunos Therapeutics Reports Second Quarter 2022 Financial Results

Aug 8, 2022, 8:50 AM EDT - 3 years ago

Alaunos Therapeutics to Report Second Quarter 2022 Financial Results on August 15, 2022

Aug 4, 2022, 5:00 PM EDT - 3 years ago

Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations

Jun 1, 2022, 11:39 AM EDT - 3 years ago

CellChorus Announces Scientific Advisory Board

Jun 1, 2022, 8:30 AM EDT - 3 years ago

Alaunos Therapeutics to Present at the Jefferies Healthcare Conference

May 26, 2022, 5:01 PM EDT - 3 years ago

Alaunos Therapeutics to Present Trials in Progress Poster for its TCR-T Library Phase 1/2 trial at the 2022 American Society of Clinical Oncology Annual Meeting

May 16, 2022, 12:31 PM EDT - 3 years ago

Alaunos Therapeutics, Inc. (TCRT) CEO Kevin Boyle on Q1 2022 Results - Earnings Call Transcript

May 16, 2022, 7:30 AM EDT - 3 years ago

Alaunos Therapeutics Reports First Quarter 2022 Financial Results

May 10, 2022, 8:30 AM EDT - 3 years ago

Alaunos Therapeutics to Present at the H.C. Wainwright Global Investment Conference

May 9, 2022, 8:30 AM EDT - 3 years ago

Alaunos Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022

May 2, 2022, 4:31 PM EDT - 3 years ago

Alaunos Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting

May 2, 2022, 8:30 AM EDT - 3 years ago

Alaunos Therapeutics Doses First Patient in TCR-T Library Phase 1/2 trial for the Treatment of Patients with Solid Tumors

Mar 30, 2022, 11:38 AM EDT - 3 years ago

Alaunos Therapeutics, Inc. (TCRT) Kevin Boyle on Q4 2021 Results - Earnings Call Transcript

Mar 30, 2022, 7:30 AM EDT - 3 years ago

Alaunos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

Mar 16, 2022, 8:30 AM EDT - 3 years ago

Alaunos Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 30, 2022

Mar 8, 2022, 4:05 PM EST - 3 years ago

Alaunos Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference

Jan 26, 2022, 11:19 AM EST - 3 years ago

Ziopharm Rebrands As Alaunos Therapeutics

Jan 26, 2022, 7:00 AM EST - 3 years ago

Ziopharm Oncology Highlights Operational Progress & Rebrands to Alaunos Therapeutics

Nov 9, 2021, 8:05 AM EST - 4 years ago

Ziopharm Oncology Presents Preclinical Data Supporting TCR-T Library Approach at the Society for Immunotherapy of Cancer 2021 Annual Meeting

Nov 8, 2021, 7:45 PM EST - 4 years ago

ZIOPHARM Oncology, Inc. (ZIOP) CEO Kevin Boyle on Q3 2021 Results - Earnings Call Transcript

Moneymastermind99 Aug. 1 at 4:29 PM

0 · Reply

Moneymastermind99 Aug. 1 at 3:33 PM

0 · Reply

Moneymastermind99 Aug. 1 at 2:30 PM

0 · Reply

mosu_trader Jul. 29 at 11:24 AM

$TCRT nice dip to buy, key levels 4.3, 6.2, 7.5

0 · Reply

katanare Jul. 24 at 5:53 PM

3 · Reply

MadMaverick Jul. 22 at 3:12 PM

2 · Reply

KhalidsCapital Jul. 19 at 3:53 AM

0 · Reply

Pipelinepivots Jul. 18 at 5:10 PM

0 · Reply

MadMaverick Jul. 16 at 5:19 PM

2 · Reply

DMAT1681 Jul. 15 at 10:25 AM

$TCRT The stock drops 20% and not a peep of insight?🤔🫡

0 · Reply

KhalidsCapital Jul. 5 at 4:19 PM

GLMD is biotech timing at its finest. A clear, public catalyst window. Strong cash position. Massive undervaluation. This isn’t a guessing game the timeline is right there. If volume shows up ahead of news, this could go vertical. $BCTX $NBSE $BIVI $TCRT

0 · Reply

ArlendMcfarland Jul. 4 at 5:50 PM

$TCRT 10x?

1 · Reply

Doozio Jul. 4 at 4:00 PM

$TCRT chop chop huckleberries let’s bang bro. 8mil market 🧢? How high can they pump Roger here during 🐒🍌🧠⏰♾️

0 · Reply

Sw1ngb0t Jun. 19 at 9:42 PM

$JUNS $SNES $TCRT $SLSN good for a pop

1 · Reply

GravyTrain1 Jun. 17 at 8:32 AM

$TCRT

0 · Reply

_www_larval_com_ Jun. 16 at 5:28 PM

$TCRT has jumped 7% higher to 2% (~279Kv) in the last few minutes, follow for more volatility.

0 · Reply

DarthGoat Jun. 16 at 4:30 PM

$TCRT Whoa! Glad I pulled the trigger just in time!

0 · Reply

theshortsqueezer2022 Jun. 16 at 3:57 PM

$TCRT patience pays folks

0 · Reply

DarthGoat Jun. 16 at 3:56 PM

$TCRT OOOUUTTT +22% All calls in real time.

0 · Reply

Ned_Nosurname May. 22 at 6:00 AM

$TCRT ''At the discretion of the board 1,639,521 shares outstanding after two reverse splits resulting in 1 for 150 previously owned 130,745 shares of which are owned by insiders. Proposal 6 asks to increase this by 1m under the employment incentive program. Current cap is 5m, so they can do this at whatever price they want. Here's the fun part... Proposal 4 allows a THIRD REVERSE SPLIT at 1:5-20 at the discretion of the board Proposal 5 allows a 10:1 SPLIT to increase shares from 5m to 50m at the discretion of the board Hmm ... wonder what option they will go for first'' https://www.investorvillage.com/smbd.asp?mb=16353&mn=122399&pt=msg&mid=25596325

0 · Reply

WAYWARD_SUN May. 15 at 4:58 AM

$TCRT

0 · Reply

PenkeTrading May. 15 at 3:47 AM

I found you a Golden Cross on the daily chart of Alaunos Therapeutics Inc. $TCRT #Alaunos #GoldenCross #NASDAQ

0 · Reply

Market Cap	4.26M
Revenue (ttm)	10,000.00
Net Income (ttm)	-4.68M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-46,800.00%
Debt to Equity Ratio	0.00

Volume	88,000
Avg Vol	50,376
Day's Range	N/A - N/A
Shares Out	1.64M
Stochastic %K	6%
Beta	-0.81
Analysts	Strong Buy
Price Target	$3.00